| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
|
J Clin Oncol
|
2010
|
13.03
|
|
2
|
Enzalutamide in metastatic prostate cancer before chemotherapy.
|
N Engl J Med
|
2014
|
11.05
|
|
3
|
Tumor antigen expression in melanoma varies according to antigen and stage.
|
Clin Cancer Res
|
2006
|
4.71
|
|
4
|
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2009
|
2.88
|
|
5
|
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
|
J Clin Oncol
|
2006
|
2.59
|
|
6
|
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
|
Eur J Cancer
|
2013
|
2.51
|
|
7
|
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
|
Urology
|
2014
|
2.09
|
|
8
|
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
|
Clin Endocrinol (Oxf)
|
2008
|
1.78
|
|
9
|
Oncology health information quality on the Internet: a multilingual evaluation.
|
Ann Surg Oncol
|
2011
|
1.73
|
|
10
|
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.
|
Cancer Immunol Immunother
|
2009
|
1.66
|
|
11
|
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.
|
Cancer Res
|
2008
|
1.64
|
|
12
|
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
|
BJU Int
|
2014
|
1.59
|
|
13
|
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
|
Blood
|
2004
|
1.54
|
|
14
|
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
|
Clin Cancer Res
|
2009
|
1.52
|
|
15
|
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs.
|
BJU Int
|
2013
|
1.50
|
|
16
|
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion.
|
BJU Int
|
2014
|
1.49
|
|
17
|
Breast and prostate cancer: more similar than different.
|
Nat Rev Cancer
|
2010
|
1.48
|
|
18
|
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
|
Med J Aust
|
2013
|
1.43
|
|
19
|
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
|
Clin Cancer Res
|
2004
|
1.41
|
|
20
|
Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer.
|
BJU Int
|
2013
|
1.39
|
|
21
|
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli.
|
Blood
|
2003
|
1.32
|
|
22
|
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
|
J Clin Oncol
|
2007
|
1.29
|
|
23
|
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells.
|
Blood
|
2003
|
1.25
|
|
24
|
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
|
Cancer Immunol Immunother
|
2008
|
1.22
|
|
25
|
Predicting clinical outcome through molecular profiling in stage III melanoma.
|
Clin Cancer Res
|
2008
|
1.17
|
|
26
|
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
|
Clin Cancer Res
|
2009
|
1.16
|
|
27
|
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
|
Cancer Immun
|
2004
|
1.15
|
|
28
|
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.
|
Proc Natl Acad Sci U S A
|
2004
|
1.11
|
|
29
|
The Ludwig institute for cancer research Melbourne melanoma cell line panel.
|
Pigment Cell Melanoma Res
|
2013
|
1.08
|
|
30
|
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
|
Cancer Immun
|
2003
|
1.08
|
|
31
|
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
|
Eur J Cancer
|
2010
|
1.05
|
|
32
|
Positron emission tomography and molecular imaging of the prostate: an update.
|
BJU Int
|
2006
|
1.03
|
|
33
|
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.
|
Immunol Cell Biol
|
2006
|
1.03
|
|
34
|
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling.
|
Blood
|
2003
|
1.03
|
|
35
|
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
|
Clin Cancer Res
|
2007
|
1.01
|
|
36
|
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
|
Am J Clin Oncol
|
2009
|
1.01
|
|
37
|
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
|
Clin Cancer Res
|
2005
|
1.00
|
|
38
|
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.
|
Eur J Immunol
|
2012
|
0.99
|
|
39
|
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
|
Clin Cancer Res
|
2013
|
0.98
|
|
40
|
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
|
BJU Int
|
2005
|
0.97
|
|
41
|
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.
|
PLoS One
|
2012
|
0.96
|
|
42
|
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
|
Cancer Res
|
2009
|
0.94
|
|
43
|
A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples.
|
J Immunol Methods
|
2004
|
0.93
|
|
44
|
Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
|
BJU Int
|
2012
|
0.93
|
|
45
|
Peripheral primitive neuroectodermal tumor arising from the seminal vesicle.
|
Urol Int
|
2008
|
0.92
|
|
46
|
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors.
|
BMC Med Genomics
|
2013
|
0.91
|
|
47
|
Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.
|
BJU Int
|
2006
|
0.91
|
|
48
|
Human perforin mutations and susceptibility to multiple primary cancers.
|
Oncoimmunology
|
2013
|
0.90
|
|
49
|
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
|
Urol Oncol
|
2009
|
0.90
|
|
50
|
Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.90
|
|
51
|
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry.
|
BJU Int
|
2014
|
0.89
|
|
52
|
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
|
Prostate
|
2009
|
0.89
|
|
53
|
The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer.
|
BJU Int
|
2012
|
0.89
|
|
54
|
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer.
|
Clin Cancer Res
|
2008
|
0.88
|
|
55
|
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
|
Cancer Immunol Immunother
|
2011
|
0.87
|
|
56
|
Cell mates: paracrine and stromal targets for prostate cancer therapy.
|
Nat Rev Urol
|
2013
|
0.87
|
|
57
|
Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy.
|
Radiother Oncol
|
2011
|
0.87
|
|
58
|
Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.
|
Cancer Immun
|
2005
|
0.85
|
|
59
|
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.
|
J Immunol
|
2006
|
0.84
|
|
60
|
Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile.
|
Stem Cells
|
2012
|
0.84
|
|
61
|
Functional imaging of renal cell carcinoma.
|
Nat Rev Urol
|
2010
|
0.84
|
|
62
|
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
|
BJU Int
|
2013
|
0.84
|
|
63
|
Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma.
|
Mol Imaging Biol
|
2006
|
0.83
|
|
64
|
Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
|
Lancet
|
2007
|
0.83
|
|
65
|
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.
|
Eur Radiol
|
2013
|
0.83
|
|
66
|
Prostate cancer immunology - an update for Urologists.
|
BJU Int
|
2010
|
0.83
|
|
67
|
Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice.
|
Int J Urol
|
2007
|
0.82
|
|
68
|
Ventricular metastasis resulting in disseminated intravascular coagulation.
|
World J Surg Oncol
|
2005
|
0.81
|
|
69
|
Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.
|
ANZ J Surg
|
2004
|
0.81
|
|
70
|
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
|
Cancer Immun
|
2005
|
0.81
|
|
71
|
A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.
|
Clin Cancer Res
|
2003
|
0.81
|
|
72
|
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2005
|
0.80
|
|
73
|
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
|
Oncology
|
2014
|
0.80
|
|
74
|
The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.
|
Twin Res Hum Genet
|
2011
|
0.79
|
|
75
|
Immunotherapy of advanced or metastatic melanoma.
|
Clin Adv Hematol Oncol
|
2007
|
0.78
|
|
76
|
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
|
Asia Pac J Clin Oncol
|
2013
|
0.78
|
|
77
|
Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
|
Cancer Immunol Immunother
|
2015
|
0.77
|
|
78
|
Melanoma vaccines: developments over the past 10 years.
|
Expert Rev Vaccines
|
2011
|
0.77
|
|
79
|
Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.
|
Asia Pac J Clin Oncol
|
2015
|
0.77
|
|
80
|
Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.
|
Asia Pac J Clin Oncol
|
2014
|
0.77
|
|
81
|
A novel method for detecting antigen-specific human regulatory T cells.
|
J Immunol Methods
|
2012
|
0.77
|
|
82
|
Targeted therapies in the treatment of renal cell carcinoma.
|
Curr Med Chem
|
2008
|
0.76
|
|
83
|
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.
|
PLoS One
|
2012
|
0.76
|
|
84
|
Extracranial oligometastatic renal cell carcinoma: current management and future directions.
|
Future Oncol
|
2014
|
0.75
|
|
85
|
Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
0.75
|
|
86
|
Urothelial cancers: using biology to improve outcomes.
|
Expert Rev Anticancer Ther
|
2012
|
0.75
|
|
87
|
Xenografting tumour beneath the renal capsule using modern surgical equipment.
|
Eur Surg Res
|
2006
|
0.75
|
|
88
|
Cancer stem cells in urologic cancers.
|
Urol Oncol
|
2009
|
0.75
|
|
89
|
Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.
|
Melanoma Res
|
2006
|
0.75
|
|
90
|
Uptake of oncology multidisciplinary meeting recommendations.
|
Med J Aust
|
2012
|
0.75
|
|
91
|
A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.
|
Melanoma Res
|
2014
|
0.75
|
|
92
|
Potential of imaging biomarkers for characterization of renal masses.
|
Expert Rev Anticancer Ther
|
2010
|
0.75
|
|
93
|
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
|
Invest New Drugs
|
2004
|
0.75
|
|
94
|
Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer.
|
Asia Pac J Clin Oncol
|
2012
|
0.75
|